Express Pharma

AUGUST 22, 2023

Lilly’s strong market capitalisation growth over Q2 was attributed to its diabetes drug Mounjaro, a synthetic peptide that reported $980 million in global sales, according to GlobalData’s Pharmaceutical Intelligence Center Drugs Database. billion by 2029, according to GlobalData’s Drugs Database. per cent), Daiichi Sankyo (-13.5

Biosimilars 97

Biosimilars Diabetes 97

European Pharmaceutical Review

AUGUST 21, 2023

Its diabetes treatment Mounjaro led this outcome. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. This is mainly due to the reported decline in sales of Humira, a consequence of biosimilar competition. billion in Q2 2023.

Biosimilars 98

Biosimilars Diabetes Vaccines 98

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Pharmaceutical Technology

JULY 15, 2022

In a budget change proposed in February and confirmed in May , California’s Department of Health Care Access and Information (HCAI) requested a one-time investment of $100 million for Newsom’s CalRx Biosimilar Insulin initiative. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin.

Biosimilars 131

Biosimilars Diabetes Documentation Packaging 131